478169-65-2

Basic information

• Product Name: 5-Benzothiazolecarboxylicacid,methylester(9CI)
• Synonyms: 5-Benzothiazolecarboxylicacid,methylester(9CI);5-Benzothiazolecarboxylicacid,Methylester;Methyl benzo[d]thiazole-5-carboxylate
• CAS NO: 478169-65-2
• Molecular Formula: C9H7NO2S
• Molecular Weight: 193.22
• Product Categories: BENZOTHIAZOLE
• Mol File: 478169-65-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Benzothiazolecarboxylicacid,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Benzothiazolecarboxylicacid,methylester(9CI)(478169-65-2)
• EPA Substance Registry System: 5-Benzothiazolecarboxylicacid,methylester(9CI)(478169-65-2)

Safety Data

• Hazardous Substances Data: 478169-65-2(Hazardous Substances Data)

Upstream product

• 7440-31-5 stannane 
• 35350-37-9 methyl 4-[[4-(methoxycarbonyl)-2-nitrophenyl]disulfanyl]-3-nitrobenzoate 
• 67-56-1 methanol 
• 68867-17-4 1,3-benzothiazole-5-carboxylic acid 
• 64-18-6 formic acid 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 

Downstream Products

• 394223-37-1 benzo[d]thiazol-5-ylmethanol 
• 1262889-04-2 5-(chloromethyl)benzo[d]thiazole 
• 68867-17-4 1,3-benzothiazole-5-carboxylic acid 

Relevant articles and documents

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease

The invention provides compounds of Formula I: wherein W0 is a bicyclic moiety and is These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which α7 is known to be involved.